Benzinga | May 6, 2021 07:48AM EDT

Intercept Pharmaceuticals Sees FY21 Ocaliva Sales $325M-$340M

Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million to $340 million and reiterates Non-GAAP adjusted operating expense guidance of $380 to $410 million